{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:24:56Z","timestamp":1791055496499,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"DOI":"10.1093\/cvr\/cvt109","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T03:32:32Z","timestamp":1367897552000},"page":"395-403","source":"Crossref","is-referenced-by-count":52,"title":["The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension"],"prefix":"10.1093","volume":"99","author":[{"given":"You-Fei","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,6]]},"reference":[{"key":"key\n\t\t\t\t20170523020404_CVT109C1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C3","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1161\/01.CIR.99.25.3266","article-title":"Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension","volume":"99","author":"Langleben","year":"1999","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C5","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1161\/CIRCULATIONAHA.109.916098","article-title":"Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target","volume":"121","author":"Archer","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1164\/rccm.200301-147OC","article-title":"Oxidative stress in severe pulmonary hypertension","volume":"169","author":"Bowers","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1752-8062.2008.00035.x","article-title":"Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension","volume":"1","author":"Masri","year":"2008","journal-title":"Clin Transl Sci"},{"key":"key\n\t\t\t\t20170523020404_CVT109C8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/01.CIR.0000093660.86242.BB","article-title":"Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS","volume":"108","author":"Griendling","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: from marvel to menace","volume":"113","author":"Forstermann","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1164\/rccm.200702-264OC","article-title":"Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats","volume":"177","author":"Kamezaki","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","article-title":"High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors","volume":"334","author":"Corbin","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20170523020404_CVT109C12","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C13","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuint.2004.03.016","article-title":"Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)","volume":"45","author":"Corbin","year":"2004","journal-title":"Neurochem Int"},{"key":"key\n\t\t\t\t20170523020404_CVT109C15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","article-title":"Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study","volume":"95","author":"Jing","year":"2009","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170523020404_CVT109C16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1096\/fj.06-7526com","article-title":"Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling","volume":"22","author":"Kirsch","year":"2008","journal-title":"FASEB J"},{"key":"key\n\t\t\t\t20170523020404_CVT109C18","first-page":"942","article-title":"Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats","volume":"231","author":"Dai","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"key\n\t\t\t\t20170523020404_CVT109C19","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.eururo.2007.11.018","article-title":"Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance","volume":"53","author":"Behr-Roussel","year":"2008","journal-title":"Eur Urol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1472-8206.2011.01013.x","article-title":"Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms","volume":"27","author":"Rashid","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.bjp.0706305","article-title":"Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells","volume":"146","author":"Muzaffar","year":"2005","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0163-7258(90)90063-8","article-title":"Activation and pulmonary toxicity of pyrrolizidine alkaloids","volume":"47","author":"Huxtable","year":"1990","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20170523020404_CVT109C23","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/ajrccm.164.6.2104033","article-title":"Increased lipid peroxidation in patients with pulmonary hypertension","volume":"164","author":"Cracowski","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","article-title":"Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats","volume":"94","author":"Abe","year":"2004","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20170523020404_CVT109C26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/76282","article-title":"Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor","volume":"6","author":"Cowan","year":"2000","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C27","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"Ignarro","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170523020404_CVT109C28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1172\/JCI41563","article-title":"Sirt1 activation protects the mouse renal medulla from oxidative injury","volume":"120","author":"He","year":"2010","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170523020404_CVT109C29","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C30","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1378\/chest.07-1682","article-title":"The 6-min walk test: clinical and research role, technique, coding, and reimbursement","volume":"135","author":"Salzman","year":"2009","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170523020404_CVT109C32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"Forstermann","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170523020404_CVT109C34","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1464-410X.2010.09270.x","article-title":"8-isoprostane F2alpha up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide","volume":"106","author":"Hotston","year":"2010","journal-title":"BJU Int"},{"key":"key\n\t\t\t\t20170523020404_CVT109C35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.freeradbiomed.2006.05.035","article-title":"8-Isoprostane-induced endothelin-1 production by infant rat pulmonary artery smooth muscle cells is mediated by Rho-kinase","volume":"41","author":"Yi","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"key\n\t\t\t\t20170523020404_CVT109C36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pupt.2010.09.003","article-title":"Peroxynitrite stimulates pulmonary artery endothelial and smooth muscle cell proliferation: involvement of ERK and PKC","volume":"24","author":"Agbani","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"key":"key\n\t\t\t\t20170523020404_CVT109C37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2710.2008.00962.x","article-title":"Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men","volume":"33","author":"Perk","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t20170523020404_CVT109C38","doi-asserted-by":"crossref","first-page":"H1038","DOI":"10.1152\/ajpheart.00097.2009","article-title":"Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure","volume":"298","author":"Redout","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C39","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.109.906818","article-title":"Oxidative stress regulates left ventricular PDE5 expression in the failing heart","volume":"121","author":"Lu","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020404_CVT109C40","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/ATVBAHA.109.201327","article-title":"A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1\/vascular endothelial growth factor pathway","volume":"30","author":"Sahara","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1124\/jpet.105.092544","article-title":"Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta","volume":"316","author":"Teixeira","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20170523020404_CVT109C42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjp.2008.141","article-title":"Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets","volume":"154","author":"Toque","year":"2008","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20170523020404_CVT109C43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/mol.105.011585","article-title":"Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+\/\u2212): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance","volume":"68","author":"Daiber","year":"2005","journal-title":"Mol Pharmacol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/99\/3\/395\/17394138\/cvt109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T11:04:33Z","timestamp":1595761473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-lookup\/doi\/10.1093\/cvr\/cvt109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,6]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,5,6]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvt109","relation":{},"ISSN":["1755-3245","0008-6363"],"issn-type":[{"value":"1755-3245","type":"electronic"},{"value":"0008-6363","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5,6]]}}}